GlassScriptPhysician profile
Michael P Falba
NPI 1275591323
$4,811.61
in general payments reported to CMS, 2019-2025
28 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $636 · 2023: $626 · 2024: $2,815 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,058 · Food and Beverage: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,058.47 |
| Food and Beverage | $1,705.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,300.00 | 2024 | |
| Gilead Sciences, INC. | $364.27 | 2022-2025 | Livdelzi, Epclusa |
| Csl Behring | $220.70 | 2021 | |
| Inari Medical, INC. | $188.16 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Axonics, INC. | $137.51 | 2021-2024 | Axonics |
| Procept Biorobotics Corporation | $128.40 | 2025 | |
| Astellas Pharma US INC | $126.00 | 2021-2023 | Xtandi, Myrbetriq |
| Genzyme Corporation | $125.00 | 2022 | |
| Urogen Pharma, INC. | $123.54 | 2023-2024 | Jelmyto |
| Alexion Pharmaceuticals, INC. | $116.63 | 2022 | |
| Optinose US, INC. | $104.48 | 2022 | |
| Alnylam Pharmaceuticals INC. | $103.29 | 2024 | Givlaari |
| Merck Sharp & Dohme LLC | $74.64 | 2023-2024 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $72.31 | 2024-2025 | Erleada, Akeega |
| Biomerieux INC | $71.77 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofire Diagnostics, LLC | $71.77 | 2021 | |
| Progenics Pharmaceuticals, INC. | $68.47 | 2022-2024 | |
| Boston Scientific Corporation | $67.27 | 2023-2025 | Ams 700, Axonics |
| Sumitomo Pharma America, INC. | $64.58 | 2023 | Gemtesa |
| Pfizer INC. | $62.33 | 2024 | |
| Teleflex LLC | $58.28 | 2024 | |
| Abc Home Medical Supply, INC. | $50.71 | 2023-2024 | |
| Urovant Sciences INC | $26.92 | 2022 | |
| Myovant Sciences INC. | $23.37 | 2022 | |
| Hologic Sales and Service, LLC | $18.29 | 2024 | Aptima |
| Hollister Incorporated | $17.14 | 2024 | |
| Endo USA, INC. | $16.34 | 2025 | Xiaflex, Aveed |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.44 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Falba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.